Peptides for energy and mitochondrial health
Almost every cell in your body runs on fuel made by mitochondria, and how well they work shapes how you feel day to day. This topic covers peptides for energy and the molecules behind it — NAD, which cells use to move energy around, and mitochondrial peptides like MOTS-c and SS-31.
The articles explain the science the way you'd want a friend to: what these compounds are, what studies show, and what's still unproven. All are prescription-only through a licensed provider.
12 articles on this topic
-
SS-31 Benefits: What Human Trials Actually Show
The clearest human evidence for SS-31 is narrow: muscle-strength findings in people with Barth syndrome. Larger trials in other mitochondrial, heart, and eye conditions have produced mixed or negative primary results.
-
NAD Injection Dosage: What Human Studies Used
There is no validated subcutaneous or intramuscular NAD+ schedule. The best-known IV pharmacokinetic study used 750 mg over six hours, so a prescriber must set route, concentration, amount and frequency together.
-
Is NAD a Peptide? What NAD+ Actually Is
NAD+ is a dinucleotide coenzyme, not a peptide. Its chemistry, cellular jobs, and evidence are different from the peptide therapies it often appears beside.
-
Peptides for Insulin Resistance: Evidence
The evidence runs from large clinical trials for semaglutide and tirzepatide to animal and observational research for MOTS-c. Those are not interchangeable levels of certainty.
-
Does Tirzepatide Make You Tired? What Trials Say
Fatigue was reported by 5–7% of trial participants on tirzepatide against 3% on placebo. The more useful question is what is actually causing it.
-
NAD Injection Side Effects: What Is Reported
Published intravenous data describe transient infusion-associated symptoms in one small retrospective series and no reported adverse events in an earlier slow-infusion pilot; because the studies differed in design and did not randomize infusion rate, they do not establish speed as the cause.
-
SS-31 Peptide Dosage: What the Trials Used
Human elamipretide studies have used multiple regimens, including weight-based intravenous infusions and, in PROGRESS-HF, 4 mg or 40 mg subcutaneously once daily; several later disease trials used 40 mg daily. Those figures are trial parameters rather than a protocol anyone can lift — outside a trial there is no established dose.
-
MOTS-c Side Effects: What Is Known and What Is Not
No completed human trial has measured them. What gets sold as a MOTS-c side-effect profile is assembled from injection-site experience with subcutaneous peptides, from pharmacology, and from what a prescriber screens for.
-
MOTS-c Dosage: Why There Is No Standard Dose
There is no established human MOTS-c dose. Published human research is mostly observational, and the numbers repeated online come largely from mouse experiments rather than clinical dosing trials.
-
SS-31 Peptide: A Patient's Guide to Elamipretide
SS-31 and elamipretide are two names for the same four-amino-acid peptide, and its branded injectable form received accelerated approval from the FDA on September 19, 2025 for a single ultra-rare genetic disease.
-
MOTS-c Peptide Benefits: Rodent Depth, Human Hints
MOTS-c is a peptide your mitochondria encode themselves — and it is studied for how cells handle fuel. The rodent evidence runs deep; the human evidence is just beginning.
-
A Patient's Guide to NAD+ Injections
NAD+ is a coenzyme found in every living cell, yet most human trial data comes from oral precursors like NR and NMN — including a 2025 meta-analysis in adults with mean ages of 61 to 83 that found no significant muscle benefit.